Benzinga's Top #PreMarket Gainers

Intercept Pharmaceuticals (NASDAQ: ICPT ) shares jumped 37.32% to $378.83 in pre-market trading. The company yesterday reported that the FLINT trial of obeticholic acid has been stopped early and the NASH primary endpoint has been met. Citigroup lifted the price target on the stock from $60.00 to $400.00. Conatus Pharmaceuticals